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Abstract Exhaled nitric oxide (ENO) has beenproposed as amarker of airway in£ammation in asthma and could be
useful to evaluate the response to anti-in£ammatory treatment.We investigated the e¡ectof budesonide andnedocro-
mil sodium on ENO levels and lung function in asthmatic children.Twenty stable steroid-na|«ve asthmatic childrenwere
randomized in a single blind, cross-over study to receive inhaled budesonide (group A) ornedocromil sodium (group B)
for 6 weeks.ENOwasmeasuredwith a chemiluminescence analyser atbaseline and atthe endof eachtreatmentperiod.
Repeated-measures ANOVAwascarriedout.In asthmatic baseline ENOlevels [mean 32?5 ppb,95% con¢denceinterval
(CI) 26?4 to 38?7] were signi¢cantly higher compared to reference values (8?7 ppb, 95% CI 8?1 to 9?2, P50?001).There
were no treatment-order e¡ect, no carry-over e¡ect and in both groups the response patternwas the same: budeso-
nide signi¢cantly lowered ENO levels from 41?0 ppb to 22?8 ppb in group A (mean, P50?001) and from 22?6 ppb to
13?0 ppb in group B, (mean, P50?05), while nedocromil did not reduce ENO values (from 24?4 ppb to 22?6 ppb in group
B and from 22?8 ppbto 38?0 ppb in group A, mean, PNS and P50?01respectively).Afterbudesonide treatment ENO
values of asthmaticswere still signi¢cantlyhigher than in healthychildren.The baseline values of FEV1and FEF25^75 were
normal in both groups and no signi¢cant changes were observed during the study. In conclusion, our study shows that
budesonide, butnotnedocromil sodium, signi¢cantlyreduces ENOlevels in stable asthmatic children evenin absence of
changes inthe lung function.c 2001Harcourt Publishers Ltd
doi:10.1053/rmed.2001.1130, available online athttp://www.idealibrary.comon
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Inhaled corticosteroids (ICS) and chromones are, for the
time being, the main long-term-control medications for
childhood asthma and are recommended as the ¢rst-line
prophylactic treatment (1,2).
ICS are highly e¡ective anti-in£ammatory agents and
recently their early introduction has been proposed for
school-aged children requiring continuous prophylactic
treatment (3,4).This strategy, however, is not universally
accepted (5). It has been shown that they may improve
symptoms, lung function and prevent complications,
such as irreversible airway damage or exacerbations (6).
Although ICS have a much lower potential for systemic
e¡ects than oral steroids, there remains the possibility
of side-e¡ects from a low level of systemic activity in pa-
tients receiving long-term therapyeven if it is notclear at
what level they become clinically signi¢cant. For theseReceived 28 December 2000 and accepted in revised form14May 2001.
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Fax: +39-049-8213502; E-mail: eugi@child.pedi.unipd.itreasons, a recent international consensus on the man-
agement of childhood asthma continues to recommend
chromones as the ¢rst-line prophylactic medication for
children (5). Some studies have supported the clinical
e⁄cacy of chromones treatment for childhood asthma
(7^10) and nedocromil sodium has been shown to inhibit
bronchoconstriction by an e¡ect on both the early and
the late asthmatic response (11). Unfortunately, speci¢c
studies to measure the anti-in£ammatory e¡ects of ne-
docromil sodium are very limited and recently the e¡ec-
tiveness of chromones as maintenance therapy in
childrenwith asthma has been questioned (12).
Recent evidence suggests that exhaled nitric oxide
(ENO) represents a sensitive, non-invasive marker for as-
sessing the degree of ongoing airway in£ammation and the
response to therapy in patients with asthma and other air-
way diseases (13^17). Nitric oxide (NO) is produced by
many cells within the respiratory tract and can be easily
detected in the exhaled air (14,15). The concentration of
ENOis increasedinpatientswith airwayin£ammation such
as asthma (16,18) andarapidreductionofENOlevelsoccurs
in asthmatics after a course of oral steroid therapy (16,19).
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weeks of treatment with budesonide and nedocromil
sodium on ENO levels and lung function in steroid-na|«ve
asthmatic children.To our knowledge, no similar studies
have previously addressed this issue in children.
METHODS
Patients
Twenty asthmatic children (13 males, seven females) ran-
ging in age from5 to14 years (9?9+0?5 years,mean+SEM)
were recruited.The patients attended the Pulmonology/
Allergy Outpatient Clinic of the Department of Paedia-
trics,University of Padova. All children hadmild or mod-
erate asthma (1) for at least 1year.Children were eligible
for our study if (a) asthma was stable, (b) they had not
received any form of regular therapy (ICS, chromones,
theophylline, long-acting b2-agonists) for at least 2
months prior to the study.Only inhaled albuterol was al-
lowedwhen needed. Stable asthmawas de¢ned as having
a forced expiratory volume in 1sec (FEV1)480% pre-
dicted, symptom-free interval, no oral steroid use and
no history of asthma exacerbation within the previous 2
months. Patients were excluded if they had su¡ered from
a respiratory tract infection in the month before ENO
measurements. The diagnosis of asthma was based on
the clinical history, examination, and pulmonary function
tests. All the subjects underwent skin-prick testing by
use of a panel of common inhalant allergens: mixed grass
pollen, Parietaria, Artemisia Vulgaris, Dermatophagoides
pteronyssinus and farinae, Alternaria and cat (Bayropharm,
Bayer, Milano, Italy). Sixteen patients were shown to be
positive to common allergens. To avoid potential con-
founding e¡ect by pollens we designed the time of the
study to be outside the grass pollen season.
Controls
Asreferencevalues for ENOweused the data previously
obtained in159 healthy children (71males and 88 females,
age range 6^15 years) using the same tidal breathing
method (20). All childrenwere caucasian,within the nor-
mal range for height and weight. There was no history
for allergy, respiratory diseases and smoking experience.
No children were taking medication and/or had had re-
cent respiratory tract infections (20).
Study design
This study was a prospective, cross-over, self-controlled,
single blind (blind to the investigator who performed
ENO measurements), randomized trial to evaluate the
e¡ects of inhaled budesonide and nedocromil sodium on
ENO and lung function in asthmatic children. Following
the screening visit, includedpatientswererandomly allo-
cated to receive either budesonide or nedocromil so-dium for 6 weeks. At the screening visit, patient
admission details and medical histories were recorded
and each subject underwent ENO measurement and
spirometry. The dosage of budesonide (Pulmaxan1 As-
tra) was 400mgday71 (200mg twice daily) under the
age of 9 years and 600mgday71 (400mg in the morning
and 200mg in the evening) after the age of 9 years. The
dosage of nedocromil sodium (Tilade1 Rhone-Poulenc)
was 4mg three times daily. Budesonide was given by a
dry powder inhaler device (Turbohaler1 Astra) and ne-
docromil sodium by MDI through a large spacer (Volu-
matic1 Glaxo). Children and parents were instructed
for the use of the two inhalation devices prior to entry
into the study.The ¢rst study treatment was given for 6
weeks (t1), then the patients were switched to the other
treatment for a further 6weeks (t2).Therewas nowash-
out between the study periods.
Patients performed ENOmeasurement and spirome-
try in three occasions: at baseline, at the end of the ¢rst
treatment (after 6 weeks, t1), and then at the end of the
second treatment (after other 6 weeks, t2). Measure-
ments were always done in the afternoon by the same
investigator whowas blinded to the treatment.ENO va-
lues of asthmatics were compared to normative data
previously obtained using the same method (20). The
protocol was approved by our institutional review
board, and informed consent was obtained from all par-
ents and patients.
Measurement of exhaledNO
ENOwasmeasured by an online tidal breathingmethod
(14,15) using a chemiluminescence analyser.The details of
the method have been previously described (16). Brie£y,
the child was asked to breathe at tidal volume, through
a mouthpiece directly connected by aTe£on tube to the
analyser via a two-way valve to avoid rebreathing.To ex-
clude the impact of environmental NO, the child inhaled
NO free-air accumulated in a collapsible reservoir. ENO
levels were continuously analysed by the chemilumines-
cence analyser (CLD 700 Al-Med, Ecophysics, Switzer-
land) sampling at a constant £ow of 0?7 lmin71. NO
levels were recorded when a steady state was reached.
In order to keep the softpalate closed (14,15), thebreath-
ing circuit was provided with an internal restrictor that
allows the exhalation with a low resistance providing a
pressure of 3^4 cmH2O at themouthpiece.Before each
study, the chemiluminescence analyser was calibrated
with a certi¢ed calibration mixture of NO in nitrogen
(NO 300ppb, NOx 308ppb) (SIAD, Bergamo, Italy)
with guaranteed stability. ENO concentrations were re-
ported in parts per billion (ppb).
Spirometry
Pulmonary function parameters were measured by
means of a 10-l bell spirometer (Biomedin, Padua, Italy),
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percentage of predicted values according to Polgar and
Promadhat (21). All patients abstained from using albu-
terol for at least12h before the test.
Statistical analysis
The primary endpoint of the study was to evaluate the
changes in ENO through the treatments.To test the hy-
pothesis that treatments modi¢ed the parameters
(ENO levels, FEV1, FEF25^75), multivariate repeated-mea-
sures analysis of variance (RMANOVA) was applied (22),
treatment being the within-subjects factor. The treat-
ment order (nedocromil/budesonide vs. budesonide/ne-
docromil) was inserted in the model as a between-
subject factor
to test the treatment-order e¡ect. If the result of
RMANOVA was signi¢cant, orthogonal contrast com-
parisonswere applied. All analyseswereperformedwith
the SPSS/PC+ statistical package (SPSS Inc, Chicago, IL,
U.S.A.).The results are expressed asmeanwith 95% con-
¢dence intervals (CI). AP-value lower than 0?05was con-
sidered as signi¢cant.
RESULTS
Subjects demographics
Twenty asthmatic children were recruited. Patients’
characteristics atbaseline arepresented inTable1. Eleven
children were randomized to receive budesonide in the
¢rst 6 weeks and then switched to nedocromil sodium
for the other 6 weeks (group A).The other nine children
(group B) received nedocromil sodium for the ¢rst 6
weeks of the study and then switched to budesonide for
the other 6 weeks.Of the 20 patients who entered the
treatment period, six were withdrawn during the last 6
weeks of treatment, ¢ve from group A and one from
group B.Five patients of groupAwerewithdrawn during
the treatment with nedocromil sodium for inadequate
asthma control. The patient in group B was withdrawn
during the treatment with budesonide due to low com-TABLE 1. Baseline patients’characteristics
Group A Group B
Number 11 9
Age (years)
mean+ SEM
11?2+0?5 8?3+0?6
Range 8^14 5^11
Sex (F/M) 8/3 5/4
Atopic 11 5
Non-atopic 0 4pliance with the therapy.Overall, six patients in group A
completed the sequence budesonide ^nedocromil and
eight patients in group B completed the sequence nedo-
cromil^budesonide.
ExhaledNO
Baseline ENO values were signi¢cantly higher in asth-
matics than in healthy children (41?0ppb, 95% CI 30?2 to
51?7 group A; 24?4ppb, 95% CI 15?8 to 33?0 group B;
8?7ppb, 95% CI 8?1 to 9?2 healthy controls, P50?001).
Randomization notwithstanding, the baseline ENO va-
lues of the two groups of asthmatic patients were di¡er-
ent, group A having a higher value. Values of ENO
decreased after budesonide, but not after nedocromil
(Fig. 1). After cross-over, the pattern was similar. RMA-
NOVA showed no signi¢cant treatment-order e¡ects
nor interactions. As the sequence of treatments did notFIG. 1. (a) Meanlevelof FEV1% predicted (95%CI) ateachper-
iodof assessment.No signi¢cantdi¡erenceswereobserveddur-
ing the study. (b) Mean levels of ENO (95% CI) at each period of
assessment during the study.Data are from subjects that com-
pletedthe study.SubjectsofgroupA (&)were ¢rsttreatedwith
budesonide for 6 weeks and then switched to nedocromil so-
dium.GroupB (*) receivedthetreatmentsinthereverseorder.
In both groups budesonide treatment was followed by a signi¢-
cant reduction of ENO values.Reference values for ENO (95%
CI) are from 159 healthy children (20). *P50?05, **P50?01,
***P50?001. P-values represent comparison between the end
and the startof eachtreatmentperiod.
TABLE 2. ENOvalues ofthe twotreatmentpooled together in14 children completing the study
Baseline
(Group A+B)
Budesonide
(Group At1+Bt2)
Di¡erence
NO (ppb) 31?5 (24 to 39) 17?2 (12?5 to 21?9)* 714?3 (721?4 to77?2)
Baseline
(Group A+B)
Nedocromil
(Group At2+Bt1)
Di¡erence
NO (ppb) 31?5 (24 to 39) 29?2 (23?0 to 35?3){ 72?3 (77?7 to 3?1)
P-values representcomparisonbetweenbaseline and the end of eachtreatment.
t1, t2 seemethods.
ENOvalues are expressed inppb, asmeanwith 95% CI.
*P50?001, {PNS.
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pooled together.The treatment e¡ect was the only fac-
tor to explain the observed di¡erences, and was highly
signi¢cant (P 0?002); contrast comparisons showed
that ENO values after nedocromil (At2+Bt1) were not
di¡erent from baseline (di¡erence 72?3ppb, 95% CI
77?7 to 3?1, P 0?38), whereas ENO values after bude-
sonide (At1+Bt2) were di¡erent frombaseline (di¡erence
714?3ppb, 95% CI721?4 to77?2, P50?001) (Table 2).
Given the di¡erence in baseline values between groups
A and B, a separate analysis was carried out within each
group. In both groups, RMANOVA showed that there
were signi¢cant di¡erences between the three times
(baseline, t1, t2).Values of ENOafter nedocromil treatment
were never di¡erent from baseline (P 0?54 in group A,
P0?57 in group B); values after budesonide treatment
were signi¢cantly reduced compared to baseline (group A
P50?001) and nedocromil treatment (group B P50?05).
Moreover, even afterbudesonide treatment, both ingroup
A and group B ENO values of asthmatics were still signi¢-
cantly higher than in healthy children (P50?01).
In order to verify a possible source of bias due to the
presence of sixdrop-outs, weperformed also an analysis
of the data of the pre-cross-over period when all pa-
tients were available.This amounts to carry out a paral-
lel-comparison design study, and allows to obtain
unbiased estimates of the e¡ects (23) (group A, n11:
baseline ENO 38.6ppb, 95% CI 30?2 to 47?1, post-treat-
ment ENO 25?8ppb, 95% CI17?1to 34?5, P50?05; group
B, n 9: baseline ENO25?1ppb,95%CI17?5 to 32?6, post
treatment ENO22?1ppb,95%CI15?3 to 28?9,PNSwith
a Student’s t-test for paired data). Also with this analysis,
theresults are similar to those already showncon¢rming
RMANOVA results, i.e. that budesonide but not nedo-
cromil sodium reduces ENO levels.
Spirometry
At baseline there were no signi¢cant di¡erences in FEV1
and FEF25^75 between the groups [95% (95%CI 83 to106)and 97% (95% CI 62 to132) in the group A and 97% (95%
CI 90 to105) and109% (95% CI 75 to 137) in group B re-
spectively, PNS]. During the study there were no sig-
ni¢cant changes in the two groups at each period of
assessment (RMANOVA,PNS) (Fig.1).
DISCUSSION
Recently, the measurement of ENO has been proposed
as a sensitive, non invasive marker to assess the extent
of airway in£ammation in asthmatic patients and moni-
tor the e¡ectiveness of anti-in£ammatory therapy
(13,17).The results of this study show that, in stable ster-
oid-na|«ve asthmatic children, 6 weeks of treatment with
inhaled budesonide signi¢cantly reduce ENO levels,
while nedocromil sodium does not signi¢cantly modify
ENO production.However, the ¢nal levels of ENO after
inhaled steroids were still increased compared to values
found in normal individuals.
The ENOreduction found after budesonide treatment
con¢rms and extends the results of previous studies that
showed a decrease in ENO levels in asthmatic patients
treated with inhaled steroids (24^26). Recently, Jataka-
non et al. (17) assessed the e¡ect of inhaled budesonide
on ENO and other in£ammatory parameters in asth-
matics. They found that, after inhaled steroids, there
was a signi¢cant reduction in ENO, an improvement in
methacholine PC20 and a reduction of sputum eosino-
phils. Similar results have been obtained by van Rensen
et al. after a 4-week treatment with £uticasone in asth-
matic adults (24).Taken together these ¢ndings support
the contention that ENOis a surrogatemarker of airway
in£ammation.
In children it has been shown that during asthma ex-
acerbation ENO is amore sensitivemarker of asthma ac-
tivity than serummarkers (ECP and soluble interleukin),
and appears to be a more useful indicator of the bene¢-
cial response to corticosteroid therapy (19). It could be
speculated that the anti-in£ammatory e¡ect of steroids
results in a down-regulation of the transcription of
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reduced production of NO. It has been suggested that
these drugs inhibit the expression of iNOS probably by
blocking the transcription factor nuclear factor-kappa B
that is critical for transcription of the iNOS gene (27).
Furthermore, the e¡ect of steroids on epithelial expres-
sion of iNOS has been con¢rmed in vivo using endobron-
chial biopsies (28).
We did not show a signi¢cant reduction of ENO after
nedocromil sodium therapy: in group A, ENO values in-
creased, while in group B they remained unchanged. It
needs to be highlighted that group A had lower baseline
ENO values because of previous budesonide treatment.
This suggests that nedocromil sodium is unable tomain-
tain the inhibition of iNOS expression reachedwith ster-
oid treatment.These ¢ndings are similar to preliminary
data reported by Al-Ali et al. in asthmatic adults (29).
They found that ENO levels are reduced by budesonide
but not by nedocromil sodium or placebo. Similarly to
ours, this study included only steroid-na|«ve asthmatic
patients.
Nedocromil sodium is considered a safe alternative to
inhaled steroids for ¢rst-line intervention inmild asthma
and several studieshave con¢rmedits clinical e⁄cacy (7^
10, 30). However, recently, the e¡ectiveness of chro-
mones has been questioned (12,31).Chromones are con-
sidered anti-in£ammatory drugs because they prevent
release of in£ammatorymediators from eosinophils, re-
duce activation and chemotaxis of these cells (32) and at-
tenuate eosinophil-induced damage of bronchial
epithelial cells (33). The mechanism of action of chro-
mones is not well understood.Their e¡ect seems to be
modulated by an inhibition of calcium channel through
chloride currents (33). This might explain why nedocro-
mil sodium treatment did not reduce ENO that, inver-
sely, was reduced by steroid therapy via the above
mentionedmechanisms.
Although our study is limitedby the single-blinddesign
and the low sample size, we found the same response
pattern (i.e. a reduction of ENO after budesonide but
not after nedocromil) in both treatment groups. Base-
line values of ENO were di¡erent at the beginning of
the study; an explanation of this ¢nding is that in group
A, that showed higher values of ENO at baseline, all pa-
tients were atopic, while in group B four out of nine pa-
tients were non-atopic. This is in keeping with recent
studies that have demonstrated that atopic asthmatic
children produce greater amount of ENO than do non-
atopic asthmatics (34).
Finally, we found that baseline ENO values were high-
er in asthmatic patients with normal lung function than
in healthy controls.This ¢nding could be expression of a
subclinical airway in£ammation, even during symptom-
free periods (34), as recently shown in childrenwith sea-
sonal asthmawhohad increased ENOalso out thepollen
season (35). It is noteworthy that after 6 weeks of bude-sonide treatment, ENO was still signi¢cantly increased
compared to healthy controls in both groups. This sug-
gests that normal values of ENO in asthmatics can prob-
ably be reached only with higher dosages of steroids or
longer treatment periods. It is indeed known that treat-
mentwith inhaled steroidsmay provide only partial sup-
pression of airway in£ammation (36) and that the e¡ect
of steroids on ENOis likely to be dose-dependent (17,25).
The inability to show an improvement in lung function
following steroid treatment, despite the improvement
of ENO, may be due to the normal baseline levels of
FEV1 (83^116% predicted), with little room for improve-
ment. It is therefore likely that the suppression of airway
in£ammation inducedby inhaled steroids in patientswith
stable asthma can not be objectively assessed by stan-
dard parameters of lung function. Similar results, i.e. a
reduction of ENOwithoutchanges in lung function, have
been found by other studies (25,35).
In conclusion, our study shows that inhaled budeso-
nide, but not nedocromil sodium, signi¢cantly reduces
ENO levels in stable, steroid-na|«ve asthmatic children
even in absence of changes in lung function.This ¢nding
suggests that ENOmaybe a reliable complement in eval-
uating the response to anti-in£ammatory treatment and
may provide additional information for assessing asthma
disease activity. Because of the aforementioned limits of
study design, further trials are necessary to evaluate the
clinical relevance of these ¢ndings.
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